Specialty biopharmaceutical company EyePoint Pharmaceuticals has selected Scott Jones as chief commercial officer and Said Saim, PhD, as chief technology officer.
Mr. Jones will focus on the commercialization of EyePoint's two FDA- approved, commercially launched eye products.
Dr. Saim will be responsible for clinical development, pharmaceutical sciences and manufacturing and operations of EyePoint's ocular treatments.
"The launches of our two ophthalmology products have been met with strong interest from both patients and treating physicians for these debilitating eye diseases," Nancy Lurker, president and CEO of EyePoint Pharmaceuticals said in a news release. "We look forward to leveraging Scott and Said’s respective expertise to drive growth of our market share."